At a glance
ClinicalIndex Comparison RecordN/ACompleted· 13 enrolled
Drug / intervention
Relizema ecofoamdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open Label, Uncontrolled Study for the Evaluation of Efficacy and Safety by Clinical Parameters of Relizema Ecofoam in Adult Atopic and Contact Dermatitis
In Brief
A clinical study evaluating Relizema ecofoam for Dermatitis. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity. The disease severity will be clinically measured through the Investigator Global Assessment (IGA) after 28 days of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartNov 2021
Primary CompletionDec 2022
Study CompletionJun 2023
TodayJul 2026
First PostedAug 11, 2021
Enrollment StartNov 15, 2021
Primary CompletionDec 29, 2022
Study CompletionJun 15, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.9 years ago
Interventions
Relizema ecofoamdevice
DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration